Dyslipidemia as Risk Factor of Atherosclerosis in Patients With Chronic Obstructive Pulmonary Disease

Abstract

Introduction: Atherosclerosis is one of the most common co-morbidities observed in chronic obstructive pulmonary disease. A better understanding of mechanisms of atherosclerosis in patients with chronic obstructive pulmonary disease is needed to improve clinical outcomes. The aim: to evaluate the plasma levels of lipid parameters, atherogenic indices, systemic inflammatory markers and to assess their relationship with the severity of chronic obstructive pulmonary disease. Materials and methods: A total of 72 subjects diagnosed with chronic obstructive pulmonary disease and 41 healthy controls, the same gender and age categories, with ≥ 10 pack years smoking history, were followed-up of about 5.8 years. Blood tests with determination of lipid profiles, atherogenic indices and systemic inflammatory markers were conducted in remaining patients who fulfilled inclusion criteria of the study. Results: Triglyceride, atherogenic index of plasma, cardiogenic risk ratio and atherogenic coefficient values were significantly higher, but high-density lipoprotein cholesterol – significantly lower in patients with chronic obstructive pulmonary disease than in controls. Lipid profiles were similar in lower-risk (stage A and B) and higher-risk (stage C and D) patients with chronic obstructive pulmonary disease. The analysis showed that atherogenic indices and serum high sensitive C-reactive protein were inversely correlated with forced expiratory volume in 1 sec, especially in higher-risk patients with chronic obstructive pulmonary disease (r = - 0.61 p < 0.05; r = - 0.57 p < 0.05; r = - 0.54 p < 0.05 and r = - 0.49 p < 0.05 respectively). Conclusions: Atherogenic indices and serum high sensitive C-reactive protein can be considered as useful biochemical markers to predict an early stage of atherosclerosis especially in higher-risk patients with chronic obstructive pulmonary disease.

Theaflavin alleviates oxidative injury and atherosclerosis progress via activating microRNA‐24‐mediated Nrf2/HO‐1 signal

“…Data presented as mean ± standard deviation (n = 6). *p < .05, **p < .01 compared with the control; # p < .05, ## p < .01 compared with cholesterol treatment group Dyslipidemia is a key risk factor for AS and is also the main pathological manifestation (Ternushchak & Tovt-Korshynska, 2019). Studies have shown that it is an effective way to prevent and treat AS by regulating blood lipid levels; currently, statins are the main therapeutic drugs for the treatment of AS because of its hypolipidemic effect (Kouhpeikar et al, 2020;Li et al, 2019).…”

Comparative Analysis of Arterial Stiffness Between Patients with Chronic Obstructive Pulmonary Disease and Healthy People

“…Arterial stiffness is a commonly used index for clinical prediction of carotid artery disease, which is a non-invasive examination. It was found that age, dyslipidemia, course of disease, V-type involvement and high mean arterial pressure were independent risk factors for increased arterial stiffness in patients with COPD [15,16] . In this study, the level of RI and PI of the patients with COPD in the observation group were lower than those in the control group (P < 0.05); the IMT, total plaque area, and number of plaques in the observation group were higher than those in the control group ( P < 0.05); The arterial stiffness and ABI level of patients with COPD in the observation group were higher than those of healthy subjects in the control group (P < 0.05), indicating that the continuous development of COPD will lead to increased arterial stiffness and abnormal ultrasound examination.…”

Study of Levels of Plasma Fibrinogen and its Association with Disease Severity in Patients with Chronic Obstructive Pulmonary Disease

“…A commonly used indicator of the severity and progression of the disease in COPD is expiratory volume per second (FEV1). However, it is weakly associated with symptoms and administration difficulties in elderly patients [6][7] . Therefore, there is a need for other markers that are better and easy to apply to sick and elderly patients.…”